Drug Shortage Report for XARELTO
| Report ID | 249406 |
| Drug Identification Number | 02510170 |
| Brand name | XARELTO |
| Common or Proper name | RIVAROXABAN |
| Company Name | BAYER INC |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVAROXABAN |
| Strength(s) | 103.4MG |
| Dosage form(s) | GRANULES FOR SUSPENSION |
| Route of administration | ORAL |
| Packaging size | 250 mL |
| ATC code | B01AF |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2025-02-05 |
| Actual start date | |
| Estimated end date | 2025-02-13 |
| Actual end date | 2025-02-03 |
| Shortage status | Avoided shortage |
| Updated date | 2025-02-03 |
| Company comments | This drug shortage report was submitted in error. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2920 MATHESON BLVD EAST MISSISSAUGA, ONTARIO CANADA L4W 5R6 |
| Company contact information | 1-800-265-7382 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2025-02-03 | French | Compare |
| v3 | 2025-02-03 | English | Compare |
| v2 | 2025-02-03 | French | Compare |
| v1 | 2025-02-03 | English | Compare |
Showing 1 to 4 of 4